John Zajecka, MD

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

August 6, 2025

Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...

Richard C. Shelton, Robert E. Litman, Howard Hassman, et al

Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

July 14, 2025

History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...

Scott T. Aaronson, Charles R. Conway, Charles Gordon, et al

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

February 1, 2023

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in some patients.

John Zajecka, Margarete A. Wallner, Joshua C. Eloge, et al

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 27, 2013

Susan G. Kornstein, Pierre Blier, John Zajecka

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 15, 2013

Susan G. Kornstein, Pierre Blier, John Zajecka

Original Research

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

August 15, 2002

Rachel Manber, David L. Dunner, Susan G. Kornstein, et al

Original Research

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

May 12, 2002

Rachel Manber, Susan G. Kornstein, Madhukar H. Trivedi, et al

Article

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

January 1, 2002

John Zajecka, Geoffry W. McEnany, Kimberly M. Lusk

Article

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

January 1, 2002

David L. Dunner, Norman Sussman, John Zajecka, et al

Original Research

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

June 1, 2001

Maurizio Fava, David L. Dunner, Madhukar H. Trivedi, et al

Article

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

February 1, 2001

John Zajecka

Article

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

February 1, 2001

John Zajecka

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

ELSEWHERE:

FOLLOW US:

John Zajecka, MD

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles